M. Brignone
Lundbeck
29 Papers
112 Citations
M. Brignone is an academic researcher from Lundbeck. The author has contributed to research in topics: Vortioxetine & Major depressive disorder. The author has an hindex of 9, co-authored 29 publications.
Chat about Author
Papers
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
TL;DR: The findings on the Digit Symbol Substitution Test indicate differential effects of various antidepressants on improving cognitive function in patients with major depressive disorder and highlighted the large variability in measures used to assess cognitive functioning.
The effect of vortioxetine on health-related quality of life in patients with major depressive disorder.
TL;DR: Vortioxetine yielded significant, meaningful HRQoL improvements in 6 MDD studies of 6 to 8 weeks' duration, and improved 12-item Health Status Questionnaire scores significantly more than placebo for the domains of health perception, mental health, and energy.
32
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Pierre-Michel Llorca,Christophe Lançon,M. Brignone,B. Rive,Samir Salah,Larry Ereshefsky,Clément François +6 more
TL;DR: Meta-regression data show that vortioxetine offers a comparable or favorable combination of efficacy and tolerability (measured by withdrawal rate due to adverse events) versus other antidepressants in registration studies in MDD.
30
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
Michael E. Thase,Natalya Danchenko,M. Brignone,Ioana Florea,F. Diamand,Paula L. Jacobsen,Eduard Vieta +6 more
TL;DR: It is suggested that vortioxetine is an effective switch therapy for patients with MDD whose response to SSRI/SNRI therapy is inadequate and well tolerated and, for Patients with a history of TESD, showed significant advantages versus escitalopram.
26
Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses.
TL;DR: Comparative network meta-analysis evaluation showed that 5-FU formulations were the most efficacious interventions examined, and 4-FU 4%, which was recently approved, showed a comparable efficacy profile to5-FU 5%, and had satisfactory acceptability outcomes.
24